Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.45 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 8/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26095982 | 1.00 | HTR2C (0.45) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL28642507 | 0.98 | HTR2C (0.44) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL26093263 | 0.87 | HTR2C (0.40) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1348972 | 0.75 | HTR2C (0.50) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2161211 | 0.75 | HTR2C (0.57) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20812486 | 0.74 | KDM4E (0.46) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL20544769 | 0.73 | HTR2C (0.55) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21736594 | 0.73 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL21736595 | 0.73 | ALDH1A1 (0.48) | ALDH1A1 | |
| Cyclo(Prolylglycyl) SCHEMBL4243772 | 0.73 | ALDH1A1 (0.48) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-115703765-A | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-2205610-B1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HTR2C 2679/4885HTR2A 3275/4885ALDH1A1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.